Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease

被引:21
作者
Dodel, Richard [1 ]
Joensson, Bengt [2 ]
Reese, Jens Peter [1 ]
Winter, Yaroslav [1 ]
Martinez-Martin, Pablo [3 ,4 ]
Holloway, Robert [5 ]
Sampaio, Cristina [6 ]
Ruzicka, Evzen [7 ]
Hawthorne, Graeme [8 ]
Oertel, Wolfgang [1 ]
Poewe, Werner [9 ]
Stebbins, Glenn [10 ]
Rascol, Oliver [11 ]
Goetz, Christopher G. [10 ]
Schrag, Anette [12 ]
机构
[1] Univ Marburg, Dept Neurol, D-35043 Marburg, Germany
[2] Stockholm Sch Econ, Dept Econ, S-11383 Stockholm, Sweden
[3] Alzheimer Ctr Reina Sofia Fdn, Alzheimer Dis Res Unit, Madrid, Spain
[4] Alzheimer Ctr Reina Sofia Fdn, Ctr Networked Biomed Res Neurodegenerat Dis CIBER, Res Ctr Neurol Dis CIEN Fdn, Carlos Inst Hlth 3, Madrid, Spain
[5] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA
[6] Fac Med Lisbon, Lisbon, Portugal
[7] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic
[8] Univ Melbourne, Dept Psychiat, Melbourne, Vic, Australia
[9] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria
[10] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA
[11] Lab Pharmacol Med & Clin, Toulouse, France
[12] UCL, Inst Neurol, London, England
关键词
Parkinson's disease; cost effectiveness; cost; health economics; cost utility; QUALITY-OF-LIFE; STATE PREFERENCES; BURDEN; ILLNESS; IMPACT; EQ-5D; COHORT; METHODOLOGY; INSTRUMENT; SEVERITY;
D O I
10.1002/mds.25571
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Health economic studies in Parkinson's disease (PD) have become increasingly common in recent years. Because several methodologies and instruments have been used to assess cost and outcomes in PD, the Movement Disorder Society (MDS) commissioned a Task Force to assess their properties and make recommendations regarding their use. A systematic literature review was conducted to explore the use of those instruments in PD and to determine which should be selected for this review. We assessed approaches to evaluate cost of illness (COI), cost effectiveness, and cost utilities, which include the use of direct (standard gamble, time trade-off. and visual analogue scales) and indirect instruments to measure health status and utilities. No validated instruments/models were identified for the evaluation of COI or cost-effectiveness in patients with PD; therefore, no instruments in this group are recommended. Among utility instruments, only a few of these outcome instruments have been used in the PD population, and only limited psychometric data are available for these instruments with respect to PD. Because psychometric data for further utility instruments in conditions other than PD already exist, the standard gamble and time trade-off methods and the EQ-5D (a European quality-of-life health states instrument) and Health Utility Index instruments met the criteria for scales that are "recommended (with limitations)," but only the EQ-5D has been assessed in detail in PD patients. The MDS Task Force recommends further study of these instruments in the PD population to establish core psychometric properties. For the assessment of COI, the Task Force considers the development of a COI instrument specifically for PD, like that available for Alzheimer's disease. (c) 2013 Movement Disorder Society
引用
收藏
页码:169 / 176
页数:8
相关论文
共 71 条
[1]
Aaronson N, 2002, QUAL LIFE RES, V11, P193
[2]
[Anonymous], 1996, COST EFFECTIVENESS H, DOI DOI 10.1093/OSO/9780195108248.001.0001
[3]
[Anonymous], GESUNDHEITSOKONOMISC
[4]
[Anonymous], QUAL LIFE RES
[5]
Projected Numbers of People With Movement Disorders in the Years 2030 and 2050 [J].
Bach, Jan-Philipp ;
Ziegler, Uta ;
Deuschl, Guenther ;
Dodel, Richard ;
Doblhammer-Reiter, Gabriele .
MOVEMENT DISORDERS, 2011, 26 (12) :2286-2290
[6]
Indirect costs in idiopathic Parkinson's disease [J].
Barth, F ;
Baum, B ;
Bremen, D ;
Meuser, T ;
Jost, WH .
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2005, 73 (04) :187-191
[7]
Bennett KJ., 1996, Quality of Life and Pharmacoeconomics in Clinical Trials, V2nd, P253
[8]
Brazier J., 1999, J Health Serv Res Policy, V4, P174, DOI [DOI 10.1177/135581969900400310, 10.1177/135581969900400310]
[9]
Mapping the eight-item Parkinson's Disease Questionnaire (PDQ-8) to the EQ-5D utility index [J].
Cheung, Y. B. ;
Tan, L. C. S. ;
Lau, P. N. ;
Au, W. L. ;
Luo, N. .
QUALITY OF LIFE RESEARCH, 2008, 17 (09) :1173-1181
[10]
Pilot randomised controlled trial of occupational therapy to optimise independence in Parkinson's disease: the PD OT trial [J].
Clarke, C. E. ;
Furmston, A. ;
Morgan, E. ;
Patel, S. ;
Sackley, C. ;
Walker, M. ;
Bryan, S. ;
Wheatley, K. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (09) :976-978